Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03040024
Other study ID # IRB00086609
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date March 17, 2017
Est. completion date April 24, 2020

Study information

Verified date July 2021
Source Emory University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this prospective randomized double blinded placebo controlled study is to investigate if a single dose of ketamine in addition to standard anesthesia will reduce the risk of delirium in otolaryngeal cancer patients postoperatively. Ketamine's effect on post-operative pain and opioid use will be measured as well. Electroencephalogram (EEG) will be utilized during the surgical procedure to evaluate its potential as a possible predictive device for delirium.


Description:

This is a single center prospective randomized double blinded placebo controlled study. The primary aim of the study is to optimize the intraoperative treatment protocol for head and neck cancer patients to reduce the incidence of delirium and associated postoperative cognitive dysfunction. Secondary aims are to determine the dose response relationship for intraoperative ketamine and delirium reduction, determine if a single dose of ketamine will reduce post-operative pain and opioid requirements, determine if raw electroencephalogram (EEG) data can predict postoperative delirium during general anesthesia, and to evaluate length of intensive care unit (ICU) and length of hospital stay. Participants will be randomized to one of three groups after administration of general anesthesia; one dose of .5 mg/kg intravenous (IV) Ketamine, 1.0 mg/kg of IV Ketamine, or IV placebo. An EEG will be used during the surgical procedure to gather raw data for off line analysis among patients developing post-operative delirium.


Recruitment information / eligibility

Status Terminated
Enrollment 71
Est. completion date April 24, 2020
Est. primary completion date February 24, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Current diagnosis of otolaryngeal cancer and undergoing surgery with general anesthesia - Competent to provide informed consent Exclusion Criteria: - Emergency surgery - Monitored Anesthesia Care (i.e., regional anesthesia alone without plans for general anesthesia) - Surgery involving the eye, eyebrow, forehead, or frontal scalp near the sensor placement - Poor health literacy - Allergy, or have experienced any drug reaction to ketamine - Pregnant or lactating - Currently in active alcohol withdrawal - Taking buprenorphine for chronic pain

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ketamine
Ketamine will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
Placebo
Placebo will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
Device:
Electroencephalogram (EEG)
A processed EEG device will be used during the surgical procedure to gather raw EEG data for off line analysis among patients developing post-operative delirium.

Locations

Country Name City State
United States Emory University Hospital Midtown Atlanta Georgia

Sponsors (1)

Lead Sponsor Collaborator
Emory University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Confusion Assessment Method fo Intensive Care Unit (CAM-ICU) Delirium Score The CAM-ICU assesses four features: 1) acute change or fluctuation in mental status from baseline, 2) inattention, 3) altered level of consciousness, and 4) disorganized thinking. The measure reports whether a participant meets criteria for delirium by summing the number of features answered as "present". Feature 1 plus 2 and either 3 or 4 present = delirium positive. Results are expressed as number of participants with or without delirium at each time frame. Baseline (Up to 30 minutes after PACU arrival), Post Operative (PACU discharge up to 6 hours)
Secondary Change in Behavioral Pain Scale (Non-Intubated) Score The Behavioral Pain Scale. Scores range from 3 (no pain) to 12 (maximum pain). Post Operation (Up to 6 Hours), Post Operation Day 0
Secondary Change in Pain Level Assessed by the Visual Analog Scale (VAS) Score Scores range from 0 (no pain) to 10 (worst pain). Baseline, Post Surgery (PACU), Post surgery (POD 0), Post surgery (POD 1), Post surgery (POD 2), Post surgery (POD 3), Post surgery (follow up visit - Up to 6 weeks)
Secondary Change in Mini Cog Score The Mini-Cog is a 3-minute instrument that can increase detection of cognitive impairment. A score ranging from 0-2 indicates positive screen for dementia. A score ranging from 3-5 indicates negative screen for dementia. Baseline, Post Surgery (Up to 6 Weeks)
Secondary Change in Mini-Mental Status Examination (MMSE) Score The MMSE is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment. Any score greater than or equal to 24 points (out of 30) indicates a normal cognition. Below this (0-24), scores can indicate cognitive impairment. Baseline, Post Surgery (Up to 6 Weeks)
Secondary Change in Cognitive Failure Questionnaire (CFQ) Score The CFQ is a 25-item self-report measure of failures in attention, perception, memory, and action. Participants are asked to indicate on a 5-point scale how often they have experienced each failure in the past months, from 0 (never) to 5 (very often). Scores range from 0 to 100 a higher score indicating more failures in attention. Baseline, Post Surgery (Up to 6 Weeks)
Secondary Post Operative Narcotics Use The total amount of narcotics used measured in morphine milligram equivalents (MME). Post Intervention (Intraoperative), Post Intervention (POD 0), Post Intervention (POD 1),Post Intervention (POD 2),Post Intervention (POD 3), Post Intervention (Follow up visit-up to 6 weeks post intervention)
Secondary Associations of Intraoperative EEG Patterns With PACU Delirium The investigators compared the relative beta power derived from the normalized power spectral density (PSD) in patients with and without PACU delirium (positive and negative delirium). Only a total of 38 EEGs with sufficient quality were analyzed. Results are expressed in percentage of cumulative power. A higher beta power correlates with worse outcome. Averages and standard deviations are shown. Intraoperative EEG and delirium during PACU stay